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Abstract
Introduction: In this era of globalization frequent traveling across the world is common. It
has resulted in exchange of knowledge and expertise among medical professionals around the
world which has a visible positive impact. However, this predisposes the travelers to the risk of
acquiring an ‘alien’ disease endemic to a particular country. This may be a great challenge for the
treating physicians to manage such patients due to lack of facility for diagnosis and experience in
handling such disease. We present a similar case scenario and problems we faced in managing that
patient.
Case presentation: A 40-year-old man visited to Africa, developed a skin rash over ankle after an
insect bite. This was followed by high grade fever. He was investigated in Kenya, however, returned
to India pending results. Later he developed sleepiness and coarse tremors. Work up for the cause of
fever was inconclusive. He was diagnosed with trypanosomiasis based on reports from Kenya. In
absence of alternate diagnosis and clinical setting, we treated him for trypanosomiasis. This therapy
resulted no improvement in patient’s condition. Finally, at request of the patient’s attendants he was
referred to Belgium where he was diagnosed as brucellosis and treated successfully.
Conclusion: Our patient was indeed suffering from neurobrucellosis. Brucellosis is a frequently
missed cause of pyrexia. Our case highlights that in this era, taking help from our professional
colleagues over the globe is easy which can improve patient care greatly.
Introduction
Globalization has affected all professionals around the
world including medical professionals significantly. It has a
great positive impact on medical professionals around the
world. It has resulted in exchange of knowledge and
expertise among medical professionals around the world
whichhas visible positive impact.However,thispredisposes
the travellers to risk of acquiring an ‘alien’ disease endemic
in that country. Lack of facility for diagnosis and experience
in handling that particular disease may be a great challenge.
We present a similar case scenario where a patient was
admittedinIndiawithprobablediagnosisofhumanAfrican
trypanosomiasis (HAT). We discuss the case and problems
faced by us managing this patient.
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A forty-year Indian, working in pharmaceutical company,
had gone on a business trip to Africa traveling through
Uganda, Tanzania and Kenya. While he was in Africa, he
developed aswelling over the left ankle joint after an insect
bite. This swelling was painful and followed by high grade
fever with chills and rigors after 3-4 days. There was no
history of any joint pain. There was no other clue on
history to localize the cause of fever. There was no history
of high risk behavior. Patient had past history of essential
tremors for last 6 years, without any functional disability.
There was no history of hypertension, diabetes, stroke, or
tuberculosis in the past. He took empirical antibiotics in
Africa which resulted minor relief in his symptoms. He
consulted a physician at Kenya, who suggested blood
investigations. However, patient had to return to India
because of personal reasons, pending his investigations
result. On examination, he was febrile with oral tempera-
ture of 102 F. He had tachycardia with pulse rate of
116/min, blood pressure was 124/80 mm of Hg. There
was an erythematous swelling over the left ankle, with
peri-lesional erythematous rashes. There was no other skin
rash elsewhere. There was no pallor, icterus, or peripheral
lymphnode enlargement. Examination of respiratory and
cardiovascular system was normal. Abdomen examination
revealed hepatomegaly of 3 cm and splenomegaly of 3 cm
below costal margin. Central nervous system examination
revealed coarse tremors in bilateral hands. Other motor,
sensory and cranial nerves examination was normal. There
were no signs of meningeal irritation.
Investigations revealed normal hemoglobin (12.8 gm/dl),
total leukocyte counts (6400/mm
3) and differential
leukocyte counts (neutrophils 54%, lymphocytes 44%,
monocytes 1% and basophils 1%) and mild thrombo-
cytopenia (100 × 10
3/mm
3). Blood biochemistry showed
normal fasting sugar (108 mg/dl), urea (26 mg/dl),
creatinine (0.8 mg/dl), calcium (8.6 mg/dl), sodium
(142 mg/dl) and potassium (4.2 mg/dl). Liver function
tests revealed mildly raised SGOT/PT (78/67 IU) and
reversed albumin:globulin (3.8/4.9 gm/dl) ratio. Erythro-
cyte sedimentation rate was 45 mm in 1
st hour measured
by Westergren’s method. Blood smear for malaria parasite
was negative. Cultures from blood and urine were sterile.
Widal test showed normal titers. Testing for viral markers
(HIV I and II, HBs Ag and anti HCV) were negative. Chest
radiograph did not show any abnormality. Contrast
enhanced computer tomographic (CECT) scan of chest
and abdomen revealed hepato-splenomegaly and an
insignificant (<1 cm) peri-pancreatic lymph node in
abdomen; no abnormality noticed in the chest.
Patient was on symptomatic treatment with antipyretics.
During hospital stay patient noticed increased sleepiness
and increased frequency and duration of tremors.
Meanwhile, we contacted, telephonically, the laboratory at
Nairobi West hospital, Kenya where patient’s blood tests
wereperformedbeforereturning to India.We weretoldthat
quantitative buffy coat (QBC) test (code no. 1021193, A/C
No. 82609, Ex No. 144572) was positive for trypanosome.
At our institute, repeat testing for trypanosome by direct
smear, giemsa and QBC testing were negative. Cerebro-
spinal fluid (CSF) examination was acellular with normal
glucose (93 mg/dl; corresponding blood glucose was
104 mg/dl). The proteins were raised (93 mg/dl) and
globulins were positive. Examination of CSF for trypano-
some by direct smear, giemsa and QBC were negative. Bone
marrow aspirate did not reveal any organism. Bone biopsy
showed single ill defined granuloma.
Magnetic resonance imaging (MRI) of brain showed mild
meningeal enhancement, most probably post lumbar
puncture enhancement. Few small lesions noticed in
pons, which were hyperintense on T2-weighted and
FLAIR images. Possibility of infective/inflammatory etiol-
ogy was kept, though these could be non specific.
Considering the fact that disease is fatal without treatment
and therapy is associated with significant morbidity, it
was a great dilemma to treat HAT based on the telephonic
reports from Kenya.However,we could notmake alternate
diagnosis. Therefore, we decided to start therapy for
HAT. In view of our lack of experience, we consulted
Dr. Ohennu Blum, WHO personnel, by e-mail for manage-
ment of HAT. He kindly advised various regimens used
for treating HAT. We arranged suramin and melarsoprol
through WHO. We decided to treat sleeping sickness
following the Tanzanian scheme for stage 2 trypanosomia-
sis. Patient received suramin, after 1.5 gm of suramin
patient became afebrile on day 3, but noticed increased
somnolence. A repeat CSF examination showed 5 WBC
(lymphocyte)/µl; sugar and protein were normal and
globulins were negative. Melarsoprol was added with
intension to give three cycles (180 mg/day × 3 days)
weekly for three weeks. However, on day 3 of first cycle
we noticed worsening of tremor. Now patient became
ataxic, although other neurological examination was
normal. So, we repeated CSF examination which showed
10 lymphocytes/µl with raised proteins. MRI of brain
showed multiple hyper-intense, minimally enhancing
white matter lesions which were reported as nonspecific.
We were continuously explaining the patient and his
attendant about the daily progress and our limited
experience of treating HAT. Patient’s attendants decided to
take patient to University Hospital at Antwerp, Belgium for
further management.
In Belgium, patient was further evaluated for cause of
symptoms complex. Initially, tuberculosis was considered
as first differential and brain biopsy was planned.
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Brucella which was further confirmed by positive culture.
Patient was started on rifampin, doxycycline plus co-
trimoxazole based regimen for 6 months. He responded
well to treatment. When last seen almost one year of
completion of therapy was asymptomatic.
Discussion
Human African trypanosomiasis and brucellosis both are
zoonotic diseases. Brucellosis is endemic in countries
bordering the Mediterranean Sea and many other countries
[1]. Humans can acquire brucellosis by direct inoculation
through cuts and skin abrasions, especially from handling
animal tissues or secretions, via the conjunctiva, inhalation
of infected aerosols and ingestion of contaminated food
suchasrawmilk,cheesesmadefromunpasteurizedmilk,or
raw meat. Clinically, brucellosis invariably presents with
fever. Systemic involvement may affect musculoskeletal
(osteomyelitis, arthritis or abscess), hepatosplenomegaly,
genitourinary (epidydimo-orchitis), central nervous system
(neurobrucellosis), cardiac (endocarditis) etc. The clinical
spectrum of neurobrucellosis is very heterogeneous. The
presentation may be with depression or lethargy or full
blown meningitis, encephalitis, polyradiculoneuritis,
cranial nerve involvement, epilepsy, brain abscess, subar-
achnoid hemorrhage and coma [2]. Examination of CSF
reveals a lymphocytic reaction with a raised protein. The
organism can be cultured from the CSF only in a minority
of cases. In suspected cases diagnosis is confirmed by
enzyme linked immunosorbant assay (ELISA) which is
positive in blood and CSF [3].
Treatment of brucellosis includes combination of drugs
which include tetracyclines, streptomycin, co-trimoxazole
(TMP-SMX) and rifampicin. The aim the treatment is to
treat current infection and prevention of relapse. Various
regimens described are Streptomycin plus doxycycline,
rifampicin plus doxycycline, or TMP-SMX with Streptomy-
cin or rifampicin (in patients who can not take tetra-
cyclines). Usual duration of treatment is 6-weeks.
However, neurobrucellosis requires a prolonged therapy
(3-6 months). With these drugs response rate is good with
relapse/failure rate of about 10% [4,5]. Our patient was
treated with rifampicin plus doxycycline for six months
and responded well.
HAT is also a zoonotic disease (affecting both wild and
domestic animals) caused by a protozoan, genus Trypano-
some (gambiense and rhodesiense spp.). Humans are
infected by the bite of Tsetse fly (Glossina spp.) which acts
as a vector. The initial lesion is characterized by formation
of chancre at site of tsetse fly bite in 5-10 days. There
are two recognized stages in the clinical presentation of
HAT – early hemolymphatic stage (early), and the late
encephalitic stage (late). Early stage is characterized by
episodes of fever (lasting 1-7 days) and generalized
lymphadenopathy usually after 1-3 weeks of bite. Other
symptoms include malaise,headache, arthralgia, lassitude,
and weight loss [6]. Infection can involve organs like
spleen, liver, skin, cardiovascular system, endocrine
system, and eyes [7]. Late stage is characterized by
neuropsychiatric manifestations. The psychiatric symp-
toms include irritability, lassitude, headache, personality
changes, hallucinations, suicidal tendencies, and mania
[7,8]. Neulogical manifestations can be motor (limb
tremors, tongue and limb muscle fasciculation, limb
hypertonia and pyramidal weakness, choreiform and
athetoid movements, dysarthria, cerebellar ataxia, and
polyneuritis) or sensory (painful hyperaesthesia, pruritus,
and deep hyperaesthesia i.e. Kerandel’s sign) [7-9]. Sleep
disturbances are characterized by lassitude, distractibility,
spontaneous, uncontrollable urges to sleep and a reversal
of the normal sleep-wake cycle. In absence of treatment
disease progresses to the final stage characterized by
seizures, severe somnolence, double incontinence, cere-
bral edema, coma, systemic organ failure, and death [7-9].
The first clue to diagnosis of HAT is a clinical presentation
in the context of a geographical location or history of
travel to an endemic area. The definite diagnosis involves
demonstration of the trypanosomes in the peripheral
blood using stained thick and thin films or in other
infected tissues such as lymph node or bone marrow
aspirates. Antibody-detecting card agglutination test is a
simple, easy and rapid test for serological diagnosis [10].
However, the most crucial part in HAT diagnosis and
therapeutic decision making is to distinguish reliably the
late encephalitic stage of HAT from the early stage as
failure to treat a patient with CNS involvement will
inevitably lead to death from the disease and inappropri-
ate CNS treatment in an early-stage patient carries a high
risk of unnecessary drug toxicity. In patients with
suspected late-stage disease it is imperative to perform a
lumbar puncture, which typically shows a lymphocytic
pleiocytosis and raised protein level of 40-200 mg/100 ml
[8]. There is lack of a universal consensus on the
operational definition of late-stage HAT. WHO criteria
for encephalytic stage are demonstration of the parasites in
the CSF or a white blood cell (WBC) count of >5/µl. Our
patient’s CSF parameters (10 lymphocytes/µl and raised
proteins) were confused with encephalitic stage of HAT.
Recently, it has been suggested that the WHO criteria
should be replaced by the presence of intrathecal IgM
synthesis or the presence of >20 WBCs/µl, independent of
the presence of trypanosomes in the CSF [11]. EEG can
show non specific changes. MRI of the brain may show
diffuse asymmetric white matter abnormalities, diffuse
hyper-intensities in the basal ganglia, and ventricular
enlargement [12]. Our case also demonstrated multiple
hyper-intense white matter lesions. CSF PCR is another
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used for therapeutic decision making [13].
Current therapy for HAT is based on four drugs namely
suramin, pentamidine, melarsoprol, and eflornithine.
Early-stage disease is treated with i.v. suramin in rhode-
siense disease and with intramuscular (i.m.) pentamidine
in gambiense disease. Melarsoprol is the only effective
drug for late-stage disease in both forms of HAT [14]. A
course of 3-4 i.v. doses are given daily over a week for a
total period of 3-4 weeks. About 80-90% patients are cured
with standard regimens [8]. Major problem with melarso-
prol treatment is a severe post-treatment reactive ence-
phalopathy (PTRE) in up to 10% of cases, with a fatality
rate of about 50% [12]. Simultaneous use of prednisolone
can reduce this complication.
Our case, probably do not add much to the exiting clinical
knowledge, however, it highlights the impact of globaliza-
tion on patients and medical professionals. In this era, both
diseases as well as medical professional expertise do not
respect the global boundaries. It has enabled us to shareour
knowledge and experiences with our professional collea-
gues over the globe within short time. It takes only few
hours to days to take professional opinion or medical aids
across the world. Similarly, it has led us to study more
closely about the diseases/conditions which are rarely seen
in that particular part of the globe. However, it has its dark
side also. As lack of experience of management of the
disease in question may be a problem. First, we may miss
diagnosis during differential diagnoses. Secondly, even if
we have considered the possibility of some ‘alien’ disease
then there are high chances of lacking facility to rule out or
confirm that possibility. Finally, it may be difficult to treat
any disease in absence of experience. Like our case was
treated wrongly as HAT. Serological test demonstrating
antibodyresponseagainst trypanosomecouldhavebeenan
option to rule out past infection however, this facility is not
available at our institute. Finally, with the help of our
professional colleagues in Belgium possibility trypnosomal
infection (past or active) was ruled out and diagnosis of
brucellosis made and treated successfully.
Conclusion
Globalization has affected whole world, including medical
professionals, in significant and positive way. It has
enabled us to exchange our professional knowledge and
expertise across the globe for better care to the patients in
need. Brucellosis is a frequently missed cause of pyrexia of
unknown. However, if suspected, diagnosis is easy and
treatment is usually satisfactory.
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